The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Shares of Arcus Biosciences (NYSE:RCUS) hit a new 52-week low on Tuesday after the biotech said that Gilead Sciences’ (NASDAQ:GILD) option rights to partner with the company for a potential anticancer ...

BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

H.C. Wainwright lowered the firm’s price target on Arcus Biosciences (RCUS) to $18 from $20 and keeps a Buy rating on the shares after the ...

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn't go as far as the takeover that some market commentators have been predicting.

With Gilead Sciences Inc. stepping away from its exclusive option rights to casdatifan in treating cancer, Arcus Biosciences Inc. has decided to move on by pricing a $150 million common stock offering ...